Emerald Health Therapeutics and STENOCARE today announced that they have received special approval from the Swedish Medicines Agency to provide medical cannabis oil to Swedish patients who have applied via their doctor to use such products for treatment purposes.
Under an agreement signed in November 2019, Emerald will supply STENOCARE with its medical cannabis products for Denmark and other markets such as Sweden.
Medical cannabis is not legalized in Sweden for general use in treatment, however, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy applied for a prescription to use medical cannabis oil as an experimental treatment of their illness. Together with the Swedish authorities, the companies are now processing the required information to commence import and distribution in Sweden. It is expected that the products will be available for patients during 2020 pending international import and export certificates.
“We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis,” said Niels V. Olsen, D.M.Sc.,an anesthesiologist at Pain and Psychiatry Center Malmö. “We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries.”
“We have a vision to help patients to improve their quality of life and we look forward to assessing the benefits of medical cannabis oil and how it impact the lives of Swedish patients,” said Thomas Skovlund Schnegelsberg, CEO of STENOCARE. “It is an important part of our new STENOCARE 2.0 Strategy to be able to introduce high quality medical cannabis products to patients and doctors, even at an early stage, into new countries. Together with our high-quality supplier, Emerald Health Therapeutics, we look forward to commence delivery of products to Sweden.”
“Helping to provide patients with high quality medical cannabis products was the foundational objective of Emerald. As we continue our business transformation, we are pleased to partner with STENOCARE and to refocus some effort on this important objective and opportunity. We are pleased to see the approval process advancing and look forward to the first delivery of our SYNCTMmedical cannabis oil products to Sweden,” said Riaz Bandali, President & CEO& of Emerald.
For more information:
Emerald Health Therapeutics
emeraldhealth.ca